TY - JOUR
T1 - A phase i study of quizartinib combined with chemotherapy in relapsed childhood leukemia
T2 - A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) study
AU - Cooper, Todd M.
AU - Cassar, Jeannette
AU - Eckroth, Elena
AU - Malvar, Jemily
AU - Sposto, Richard
AU - Gaynon, Paul
AU - Chang, Bill H.
AU - Gore, Lia
AU - August, Keith
AU - Pollard, Jessica A.
AU - DuBois, Steven G.
AU - Silverman, Lewis B.
AU - Oesterheld, Javier
AU - Gammon, Guy
AU - Magoon, Daniel
AU - Annesley, Colleen
AU - Brown, Patrick A.
N1 - Publisher Copyright:
© 2016 American Association for Cancer Research.
PY - 2016/8/15
Y1 - 2016/8/15
N2 - Purpose: To determine a safe and biologically active dose of quizartinib (AC220), a potent and selective class III receptor tyrosine kinase (RTK) FLT3 inhibitor, in combination with salvage chemotherapy in children with relapsed acute leukemia. Experimental Design: Quizartinib was administered orally to children with relapsed AML or MLL-rearranged ALL following 5 days of high-dose cytarabine and etoposide (AE). A 3+3 dose escalation design was used to identify a safe and biologically active dose. Plasma inhibitory assay (PIA) testing was performed weekly to determine biologic activity. Results: Toxicities were consistent with intensive relapsed leukemia regimens. One of 6 patients experienced a dose-limiting toxicity (DLT) at 40 mg/m2/day (elevated lipase) and 1 of 9 had a DLT (hyperbilirubinemia) at the highest tested dose of 60mg/m2/day. Of 17 response evaluable patients, 2 had complete response (CR), 1 complete response without platelet recovery (CRp), 1 complete response with incomplete neutrophil and platelet recovery (CRi), 10 stable disease (SD), and 3 progressive disease (PD). Of 7 FLT3-ITD patients, 1 achieved CR, 1 CRp, 1 Cri, and 4 SD. FLT3-ITD patients, but not FLT3 wild-type (WT) patients, had significantly lower blast counts post-quizartinib. FLT3 phosphorylation was completely inhibited in all patients. Conclusions: Quizartinib plus intensive chemotherapy is well tolerated at 60 mg/m2/day with near complete inhibition of FLT3 phosphorylation in all patients. The favorable toxicity profile, pharmacodynamic activity, and encouraging response rates warrant further testing of quizartinib in children with FLT3-ITD AML. Clin Cancer Res; 22(16); 4014-22.
AB - Purpose: To determine a safe and biologically active dose of quizartinib (AC220), a potent and selective class III receptor tyrosine kinase (RTK) FLT3 inhibitor, in combination with salvage chemotherapy in children with relapsed acute leukemia. Experimental Design: Quizartinib was administered orally to children with relapsed AML or MLL-rearranged ALL following 5 days of high-dose cytarabine and etoposide (AE). A 3+3 dose escalation design was used to identify a safe and biologically active dose. Plasma inhibitory assay (PIA) testing was performed weekly to determine biologic activity. Results: Toxicities were consistent with intensive relapsed leukemia regimens. One of 6 patients experienced a dose-limiting toxicity (DLT) at 40 mg/m2/day (elevated lipase) and 1 of 9 had a DLT (hyperbilirubinemia) at the highest tested dose of 60mg/m2/day. Of 17 response evaluable patients, 2 had complete response (CR), 1 complete response without platelet recovery (CRp), 1 complete response with incomplete neutrophil and platelet recovery (CRi), 10 stable disease (SD), and 3 progressive disease (PD). Of 7 FLT3-ITD patients, 1 achieved CR, 1 CRp, 1 Cri, and 4 SD. FLT3-ITD patients, but not FLT3 wild-type (WT) patients, had significantly lower blast counts post-quizartinib. FLT3 phosphorylation was completely inhibited in all patients. Conclusions: Quizartinib plus intensive chemotherapy is well tolerated at 60 mg/m2/day with near complete inhibition of FLT3 phosphorylation in all patients. The favorable toxicity profile, pharmacodynamic activity, and encouraging response rates warrant further testing of quizartinib in children with FLT3-ITD AML. Clin Cancer Res; 22(16); 4014-22.
UR - http://www.scopus.com/inward/record.url?scp=84982091466&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84982091466&partnerID=8YFLogxK
U2 - 10.1158/1078-0432.CCR-15-1998
DO - 10.1158/1078-0432.CCR-15-1998
M3 - Article
C2 - 26920889
AN - SCOPUS:84982091466
SN - 1078-0432
VL - 22
SP - 4014
EP - 4022
JO - Clinical Cancer Research
JF - Clinical Cancer Research
IS - 16
ER -